Alector Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.36%.
Did ALEC Beat Earnings? Q2 2025 Results
Alector delivered a notably cleaner quarter than Wall Street had anticipated, with the neuroscience biotech posting a Q2 2025 loss of $0.30 per share against a consensus estimate of $0.47, a beat of 36.17%, while collaboration revenue of $7.87 million cleared the $2.80 million estimate by 180.73%. The headline driver behind the improved bottom line was a sharp pullback in R&D spending, which fell to $27.61 million from $46.31 million a year ago, reflecting reduced activity on the AL002 and latozinemab programs following the satisfaction of key performance obligations and workforce reductions. Revenue, however, did retreat 47.8% year-over-year from $15.08 million, underscoring the lumpy nature of collaboration income. The company updated full-year guidance for collaboration revenue of $13 million to $18 million, with $307.28 million in cash providing a runway into the second half of 2027. Analysts have recently upgraded their 2025 estimates following the results, with attention centering squarely on topline data from the pivotal INFRONT-3 Phase 3 latozinemab trial in FTD-GRN, expected by mid-Q4 2025, and potential BLA and MAA submissions in 2026.
- Lower R&D expenses due to reduced spending on AL002 and latozinemab programs and headcount reductions
- Revenue decline driven by satisfaction of performance obligations for AL002 and latozinemab FTD-C9orf72 Phase 2 trial in Q4 2024
“The topline results from the pivotal INFRONT-3 Phase 3 trial of latozinemab, expected by mid- fourth quarter, represent a key inflection point for Alector and for the FTD community. FTD is a devastating form of dementia that affects people in the prime of life, with no approved treatments, and is often fatal within a decade of diagnosis. Heterozygous loss-of-function mutations in the GRN gene reduce progranulin levels by about 50%, impairing neuronal function and driving neurodegeneration. Latozinemab, our investigational therapy for FTD-GRN being developed in collaboration with GSK, is designed to restore progranulin levels in the brain. Supported by data from an open-label Phase 2 study, the FDA granted Breakthrough Therapy designation to latozinemab. The INFRONT-3 results will inform our next steps toward potential registration and may bring us one step closer to delivering a treatment for this relentless disease.”
Alector CEO, on the earnings call
Forward Guidance & Outlook
Management updated 2025 full-year guidance: collaboration revenue of $13 million to $18 million, total R&D expenses of $130 million to $140 million, and total G&A expenses of $55 million to $65 million. Cash, cash equivalents, and investments of $307.3 million are expected to fund operations into the second half of 2027. Topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN is expected by mid-Q4 2025, with potential BLA and MAA submissions in 2026 pending trial outcome. The Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease is expected to complete in 2026. Clinical entry for ADP037-ABC and ADP050-ABC is targeted for 2026.
ALEC YoY Financials
ALEC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.